Aurobindo Pharma, a Rs.5,775 crore plus pharma major, has registered strong growth in EBDITA during the second quarter ended September 2013 on account of higher sales in US, Europe and RoW. Its consolidated EBDITA moved up sharply by 72.6 per cent to Rs.443.46 crore from Rs.256.87 crore in the corresponding period of last year. However, Aurobindo's net profit improved only by 5.7 per cent to Rs.234.05 crore from Rs.222.35 crore due to forex loss of Rs.68.29 crore as against forex gain of Rs.117.67 crore in the similar period of last year. The interest cost declined by 26.6 per cent to Rs.24.58 crore from Rs.33.50 crore.  Its EPS worked out to Rs.8.07 as against Rs.7.64 in the last period.

Its consolidated net sales increased by 28.1 per cent to Rs.1,897 crore from Rs.1,481 crore. Net sales include dossier income of Rs.6.25 crore as against Rs.11.66 crore in the same period of last year. Its formulations sales increased by 36.1 per cent to Rs.1,228 crore from Rs.903 crore and that of APIs moved up 15.4 per cent to Rs.718 crore from Rs.622 crore. Its US formulation sales increased by 72 per cent to Rs.731 crore from Rs.425 crore and that in Europe & RoW moved up by 17.1 per cent to Rs.264 crore from Rs.226 crore.

The standalone net profit declined by 24.5 per cent to Rs.179.70 crore and its standalone net sales improved by 15.3 per cent to Rs.1,5816 crore.

N Govindarajan, managing director, said, “The integrated business in generic formulations is auguring well to drive the operating performance of the company. We are also investing in specific new, differentiated products offerings such as oncology, hormones, peptides and OTC business which we believe will complement our business in the coming years.”

The company filed 13 ANDAs with US FDA and its cumulative filings reached at 294. Similarly, it filed 8 DMFs during the second quarter and cumulative total reached at 175. Further, it filed 47 API DMF/COS in other key regulated market. The cumulative approvals in US stood at 184 ANDAs, followed by South Africa 64, Australia 46, and Canada 39.

For the first half ended September 2013, Aurobindo's consolidated net sales moved up by 34.3 per cent to Rs.3,597 crore from Rs.2,678 crore in the similar period of last year. Its net profit went up sharply to Rs.253.55 crore from Rs.93.44 crore, a growth of over 171 per cent. Its formulation sales went up 49.5 per cent to Rs.2,329 crore from Rs.1,558 crore and that of APIs increased by 12.9 per cent to Rs.1,365 crore from Rs.1,209 crore. The formulation sales in US jumped by 80 per cent to Rs.1,356 crore and that in Europe & RoW increased by 33.1 per cent to Rs.548 crore from Rs.412 crore in the similar first half of last year.